{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 267,
  "pageCount": 415,
  "prevPage": 266,
  "nextPage": 268,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a combination of narrative text, a screenshot of a YouTube video, and snippets of press articles to build a case of poor judgment or questionable association.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/267",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-267",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Miller appears to have a pattern of association with questionable PWS therapies, as evidenced by her recent efforts on behalf of Tryptamine Therapeutics (ASX:TYP), an Australian microcap stock promotion focused on “precision psychedelic therapy.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2ac-ee248e3ddd85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.07,
        "y": 0.37
      },
      "kind": "image",
      "text": "YouTube video screenshot showing Miller and Jim Gilligan",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffe82f73-b0a9-4d93-86cd-e8934d85af7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.41,
        "x": 0.52,
        "y": 0.37
      },
      "kind": "paragraph",
      "text": "Tryp Therapeutics Stumbles as FDA Halts Eating Disorder Study. Tryp Therapeutics Readies First Trial of TRP-8802 for Excessive Appetite...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "805c2087-21d1-4974-8a12-ca4f0992ff8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"We are pleased to announce the involvement of Dr. Miller, a leading expert in treating patients with rare eating disorders, in the planning for a clinical trial evaluating the safety, pharmacokinetics and efficacy of TRP-8802, Jim Kuo, Tryp's CEO, said in a press release.\" — Jim Kuo",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2ac-f0157355d34c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: https://www.youtube.com/watch?v=-UoH5V-oN6c; https://www.biospace.com/fda-slaps-clinical-hold-on-tryp-s-eating-disorder-trial; https://praderwillinews.com/news/tryp-therapeutics-launch-first-trial-trp-8802-excessive-appetite-pws-prader-willi-syndrome/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a9b5c0f-919d-4ddb-9a9b-166f2785ec3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Miller appears to have a pattern of association with questionable PWS therapies, as evidenced by her recent efforts on behalf of Tryptamine Therapeutics (ASX:TYP), an Australian microcap stock promotion focused on “precision psychedelic therapy.” A 2021 YouTube video with Miller and Tryptamine’s President talks up the potential for psilocybin for PWS. Predictably, the FDA placed a clinical hold and halted its Phase 2 trial in 2021.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41add41a-4b7f-488d-83a3-1d79addfc7fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.32
      },
      "kind": "title",
      "text": "Miller and Tryptamine Therapeutics – YouTube video and press articles",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c03d3e6e-0854-4985-a4f5-0b8c7103b8e2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "526c22e7-945a-43c7-892a-dcecf83ebbb3",
      "evidence": "The slide explicitly links a subject to a failed/questionable clinical trial to establish a pattern of poor association.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}